161 related articles for article (PubMed ID: 1390139)
1. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity.
McHenry PM; Bingham EA; Callender ME; Delvin PB; O'Hara MD; Ferguson WR; Laird JD; Burrows D
Br J Dermatol; 1992 Aug; 127(2):122-5. PubMed ID: 1390139
[TBL] [Abstract][Full Text] [Related]
2. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
Malatjalian DA; Ross JB; Williams CN; Colwell SJ; Eastwood BJ
Can J Gastroenterol; 1996 Oct; 10(6):369-75. PubMed ID: 9193771
[TBL] [Abstract][Full Text] [Related]
4. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
5. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?
Aithal GP; Haugk B; Das S; Card T; Burt AD; Record CO
Aliment Pharmacol Ther; 2004 Feb; 19(4):391-9. PubMed ID: 14871278
[TBL] [Abstract][Full Text] [Related]
6. Liver damage due to methotrexate in patients with psoriasis.
Dahl MG; Gregory MM; Scheuer PJ
Br Med J; 1971 Mar; 1(5750):625-30. PubMed ID: 5548839
[TBL] [Abstract][Full Text] [Related]
7. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis.
O'Connor GT; Olmstead EM; Zug K; Baughman RD; Beck JR; Dunn JL; Seal P; Lewandowski JF
Arch Dermatol; 1989 Sep; 125(9):1209-17. PubMed ID: 2774596
[TBL] [Abstract][Full Text] [Related]
8. The value of a baseline liver biopsy prior to methotrexate treatment.
Dolan OM; Burrows D; Irvine A; Walsh M
Br J Dermatol; 1994 Dec; 131(6):891-4. PubMed ID: 7857846
[TBL] [Abstract][Full Text] [Related]
9. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
Lynch M; Higgins E; McCormick PA; Kirby B; Nolan N; Rogers S; Lally A; Vellinga A; Omar H; Collins P
JAMA Dermatol; 2014 Aug; 150(8):856-62. PubMed ID: 24964792
[TBL] [Abstract][Full Text] [Related]
10. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate.
Mitchell D; Smith A; Rowan B; Warnes TW; Haboubi NY; Lucas SB; Chalmers RJ
Br J Dermatol; 1990 Jan; 122(1):1-7. PubMed ID: 2297495
[TBL] [Abstract][Full Text] [Related]
11. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
[TBL] [Abstract][Full Text] [Related]
12. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
Berends MA; Snoek J; de Jong EM; Van Krieken JH; de Knegt RJ; van Oijen MG; van de Kerkhof PC; Drenth JP
Liver Int; 2007 Jun; 27(5):639-45. PubMed ID: 17498249
[TBL] [Abstract][Full Text] [Related]
14. Transient Elastography May Improve Detection of Liver Fibrosis in Psoriasis Patients Treated with Methotrexate.
Talme T; Nikamo P; Rosenberg P; Ståhle M
Acta Derm Venereol; 2017 Aug; 97(8):952-954. PubMed ID: 28422266
[No Abstract] [Full Text] [Related]
15. Liver biopsy in methotrexate-treated psoriatics-a re-evalution.
Zachariae H; Grunnet E; Sogaard H
Acta Derm Venereol; 1975; 55(4):291-6. PubMed ID: 52258
[TBL] [Abstract][Full Text] [Related]
16. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis.
Ashton RE; Millward-Sadler GH; White JE
J Invest Dermatol; 1982 Oct; 79(4):229-32. PubMed ID: 7130740
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate hepatotoxicity and concentrations of methotrexate and folate in erythrocytes--relation to liver fibrosis and cirrhosis.
Zachariae H; Schrøder H; Foged E; Søgaard H
Acta Derm Venereol; 1987; 67(4):336-40. PubMed ID: 2445154
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsies and methotrexate: a time for reconsideration?
Zachariae H
J Am Acad Dermatol; 2000 Mar; 42(3):531-4. PubMed ID: 10688735
[No Abstract] [Full Text] [Related]
19. Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage.
Rademaker M; Webb JA; Lowe DG; Meyrick-Thomas RH; Kirby JD; Munro DD
Br J Dermatol; 1987 Sep; 117(3):311-6. PubMed ID: 3676081
[TBL] [Abstract][Full Text] [Related]
20. Liver biopsies upsilon liver scans in methotrexate-treated patients with psoriasis.
Geronemus RG; Auerbach R; Tobias H
Arch Dermatol; 1982 Sep; 118(9):649-51. PubMed ID: 7114866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
